Etirinotecan Pegol (NKTR-102) in NSCLC

Summary

This Phase 2 study is designed to characterize the objective response rate (defined as complete response (CR) and partial response (PR)) of Etirinotecan pegol administered to subjects with metastatic and recurrent NSCLC after failure of 2nd line therapy. Up to 37 eligible subjects will receive the investigational drug q3 weeks until they are no longer benefiting.

Timeline

Start

2013-01

Primary completion

2016-01

Completion

2017-03-15

Drugs

Indications